Potential Clinical Application of Genomics in Multiple Myeloma

doi:10.3390/ijms19061721

Review

. 2018 Jun 10;19(6):1721.

doi: 10.3390/ijms19061721.

Potential Clinical Application of Genomics in Multiple Myeloma

Cinnie Yentia Soekojo¹, Sanjay de Mel², Melissa Ooi³, Benedict Yan⁴, Wee Joo Chng^{5

6}

Affiliations

¹ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. cinnie_yentia_soekojo@nuhs.edu.sg.
² Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. sanjay_widanalage@nuhs.edu.sg.
³ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. melissa_ooi@nuhs.edu.sg.
⁴ Department of Laboratory Medicine, National University Hospital, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. benedict_yan@nuhs.edu.sg.
⁵ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. mdccwj@nus.edu.sg.
⁶ Cancer Science Institute of Singapore, National University of Singapore,14 Medical Drive, Singapore 117599, Singapore. mdccwj@nus.edu.sg.

PMID: 29890777
PMCID: PMC6032230
DOI: 10.3390/ijms19061721

Review

Potential Clinical Application of Genomics in Multiple Myeloma

Cinnie Yentia Soekojo et al. Int J Mol Sci. 2018.

. 2018 Jun 10;19(6):1721.

doi: 10.3390/ijms19061721.

Authors

Cinnie Yentia Soekojo¹, Sanjay de Mel², Melissa Ooi³, Benedict Yan⁴, Wee Joo Chng^{5

6}

Affiliations

¹ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. cinnie_yentia_soekojo@nuhs.edu.sg.
² Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. sanjay_widanalage@nuhs.edu.sg.
³ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. melissa_ooi@nuhs.edu.sg.
⁴ Department of Laboratory Medicine, National University Hospital, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. benedict_yan@nuhs.edu.sg.
⁵ Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore. mdccwj@nus.edu.sg.
⁶ Cancer Science Institute of Singapore, National University of Singapore,14 Medical Drive, Singapore 117599, Singapore. mdccwj@nus.edu.sg.

PMID: 29890777
PMCID: PMC6032230
DOI: 10.3390/ijms19061721

Abstract

Multiple myeloma is a heterogeneous disease with different characteristics, and genetic aberrations play important roles in this heterogeneity. Studies have shown that these genetic aberrations are crucial in prognostication and response assessment; recent efforts have focused on their possible therapeutic implications. Despite many emerging studies being published, the best way to incorporate these results into clinical practice remains unclear. In this review paper we describe the different genomic techniques available, including the latest advancements, and discuss the potential clinical application of genomics in multiple myeloma.

Keywords: gene expression profiling; genomics; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

LRP1B Polymorphisms Are Associated with Multiple Myeloma Risk in a Chinese Han Population.
Li B, Liu C, Cheng G, Peng M, Qin X, Liu Y, Li Y, Qin D. Li B, et al. J Cancer. 2019 Jan 1;10(3):577-582. doi: 10.7150/jca.28905. eCollection 2019. J Cancer. 2019. PMID: 30719154 Free PMC article.
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.
Karimi F, Aghaei M, Saki N. Karimi F, et al. Curr Treat Options Oncol. 2025 Mar;26(3):197-212. doi: 10.1007/s11864-025-01295-8. Epub 2025 Mar 5. Curr Treat Options Oncol. 2025. PMID: 40042740 Review.
Association between interleukin gene polymorphisms and multiple myeloma susceptibility.
Shahzad MN, Ijaz I, Naqvi SSZH, Yan C, Lin F, Li S, Huang C. Shahzad MN, et al. Mol Clin Oncol. 2020 Mar;12(3):212-224. doi: 10.3892/mco.2020.1979. Epub 2020 Jan 16. Mol Clin Oncol. 2020. PMID: 32064097 Free PMC article.
Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells.
Lamorte D, Faraone I, Laurenzana I, Milella L, Trino S, De Luca L, Del Vecchio L, Armentano MF, Sinisgalli C, Chiummiento L, Russo D, Bisaccia F, Musto P, Caivano A. Lamorte D, et al. Int J Mol Sci. 2018 Oct 26;19(11):3348. doi: 10.3390/ijms19113348. Int J Mol Sci. 2018. PMID: 30373165 Free PMC article.

References

1. Landgren O., Morgan G.J. Biologic frontiers in multiple myeloma: From biomarker identification to clinical practice. Clin. Cancer Res. 2014;20:804–813. doi: 10.1158/1078-0432.CCR-13-2159. - DOI - PMC - PubMed
1. Wan T.S. Cancer cytogenetics: Methodology revisited. Ann. Lab. Med. 2014;34:413–425. doi: 10.3343/alm.2014.34.6.413. - DOI - PMC - PubMed
1. Howe B., Umrigar A., Tsien F. Chromosome preparation from cultured cells. JoVE J. 2014:e50203. doi: 10.3791/50203. - DOI - PMC - PubMed
1. Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., Blood E., Oken M.M., Santana-Davila R., Gonzalez-Paz N., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567. doi: 10.1182/blood-2003-02-0493. - DOI - PubMed
1. Smadja N.V., Fruchart C., Isnard F., Louvet C., Dutel J.L., Cheron N., Grange M.J., Monconduit M., Bastard C. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia. 1998;12:960–969. doi: 10.1038/sj.leu.2401041. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Landgren O., Morgan G.J. Biologic frontiers in multiple myeloma: From biomarker identification to clinical practice. Clin. Cancer Res. 2014;20:804–813. doi: 10.1158/1078-0432.CCR-13-2159. - DOI - PMC - PubMed

[2] Landgren O., Morgan G.J. Biologic frontiers in multiple myeloma: From biomarker identification to clinical practice. Clin. Cancer Res. 2014;20:804–813. doi: 10.1158/1078-0432.CCR-13-2159. - DOI - PMC - PubMed

[3] Wan T.S. Cancer cytogenetics: Methodology revisited. Ann. Lab. Med. 2014;34:413–425. doi: 10.3343/alm.2014.34.6.413. - DOI - PMC - PubMed

[4] Wan T.S. Cancer cytogenetics: Methodology revisited. Ann. Lab. Med. 2014;34:413–425. doi: 10.3343/alm.2014.34.6.413. - DOI - PMC - PubMed

[5] Howe B., Umrigar A., Tsien F. Chromosome preparation from cultured cells. JoVE J. 2014:e50203. doi: 10.3791/50203. - DOI - PMC - PubMed

[6] Howe B., Umrigar A., Tsien F. Chromosome preparation from cultured cells. JoVE J. 2014:e50203. doi: 10.3791/50203. - DOI - PMC - PubMed

[7] Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., Blood E., Oken M.M., Santana-Davila R., Gonzalez-Paz N., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567. doi: 10.1182/blood-2003-02-0493. - DOI - PubMed

[8] Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., Blood E., Oken M.M., Santana-Davila R., Gonzalez-Paz N., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567. doi: 10.1182/blood-2003-02-0493. - DOI - PubMed

[9] Smadja N.V., Fruchart C., Isnard F., Louvet C., Dutel J.L., Cheron N., Grange M.J., Monconduit M., Bastard C. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia. 1998;12:960–969. doi: 10.1038/sj.leu.2401041. - DOI - PubMed

[10] Smadja N.V., Fruchart C., Isnard F., Louvet C., Dutel J.L., Cheron N., Grange M.J., Monconduit M., Bastard C. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia. 1998;12:960–969. doi: 10.1038/sj.leu.2401041. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Potential Clinical Application of Genomics in Multiple Myeloma

Affiliations

Potential Clinical Application of Genomics in Multiple Myeloma

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical